Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET

Date : 01/07/2020 @ 07:45
Source : PR Newswire (US)

Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET

STOCKHOLM, July 1, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - June 2020 on Friday, July 1, 2020, at 08:00 a.m. CET.

BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on July 10, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January - June 2020 followed by a Q&A-session.

To attend, please dial-in at one of the numbers below, from:
Sweden: +46-8-505-583-55
Denmark: +45-781-501-09
Germany: +49-692-222-203-77
The Netherlands: +31-207-219-495
Norway: +47-239-639-38
Switzerland: +41-225-675-632
UK: +44-333-300-9262
US: +1-833-526-8382

Webcast: https://tv.streamfabriken.com/bioarctic-q2-2020  

The webcast will afterwards also be available on demand at BioArctic's corporate website https://www.bioarctic.se/en/section/investors/presentations/

This information was submitted for publication at 08:30 a.m. CET on July 1, 2020.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and outlicensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

For more information, please contact:
Oskar Bosson
VP Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se
Tel: +46-704-10-71-80

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/invitation-to-presentation-of-bioarctic-s-interim-report-for-the-period-january---june-2020-on-july-,c3144489

The following files are available for download:

https://mb.cision.com/Main/9978/3144489/1271535.pdf

Release

Copyright 2020 PR Newswire

ADVFN Advertorial
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200706 07:14:18